Vimian Group Acquires Italian Veterinary Diagnostics Firm

Vimian Group AB, a prominent player in the global animal health arena, has significantly expanded its footprint in the companion animal diagnostics sector through a strategic acquisition in Italy. The Stockholm-based entity has finalized an agreement to absorb I-Vet srl and Biofleet srl, entities previously under the ownership of the Franzini family. This move marks Vimian's fifth strategic transaction of the year, underscoring its aggressive growth trajectory.

The integration of I-Vet, a leading Italian provider of veterinary laboratory services and in-clinic diagnostic tools since its inception in 2012, is poised to enhance Vimian's capabilities. With a dedicated team of 75 professionals, I-Vet currently serves an impressive network of approximately 5,000 veterinary clinics across Italy. Its operational model leverages a robust e-commerce platform alongside a direct sales force, ensuring broad market penetration. Furthermore, I-Vet actively contributes to veterinary education through over 100 annual courses and specialized residency programs developed in collaboration with Italian universities.

Financially, I-Vet demonstrates a strong performance, generating annual revenues in the vicinity of EUR 5.6 million, coupled with a consistent record of profitable expansion. The financial backing for this acquisition comes from Vimian's existing capital reserves, with projections indicating a minimal effect on the company's earnings per share for 2026. This financial prudence highlights Vimian's strategic approach to value creation.

Following the acquisition, Daniele Franzini, the current CEO of I-Vet, will continue to steer the company's operations under the Vimian Group umbrella. The newly acquired businesses will be seamlessly integrated into Vimian's dedicated Diagnostics segment, a division specifically focused on advancing diagnostic solutions for companion animals. This strategic alignment is expected to yield significant synergies and operational efficiencies.

This acquisition directly supports Vimian's overarching strategy to fortify its position in the rapidly expanding Italian veterinary diagnostics market. The broader animal health diagnostics market is experiencing robust growth, driven by increasing pet ownership, a greater emphasis on preventative care, and advancements in diagnostic technologies. Industry reports suggest the global veterinary diagnostics market is projected to reach substantial figures in the coming years, making strategic acquisitions like this crucial for market leaders.

The transaction is emblematic of a broader trend of consolidation within the European veterinary diagnostics landscape. Established platform companies are increasingly targeting specialized regional players that possess strong client relationships and unique technological capabilities. Vimian Group, with its global reach of over 17,000 veterinary clinics across more than 80 markets and annual revenues of approximately EUR 375 million, is well-positioned to capitalize on these market dynamics.